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BOB.1/OBF.1 (also called OCA-B), a B lymphocyte-specific transcriptional coactivator, is
recruited to octamer-containing promoters by interacting with the Oct-1 or Oct-2 proteins.
BOB.1/OBF.1-deficient mice show impaired secondary immunoglobulin isotype secretion
and complete absence of germinal centers. Furthermore, numbers of splenic B cells are
reduced due to a developmental block at the transitional B cell stage in the bone marrow. We
found that surface expression of CD22 is selectively increased on B lineage cells in the bone
marrow of BOB.1/OBF.1-deficient mice. CD22 is known as a negative regulator of B cell
receptor signaling. We therefore investigated whether defects in B cell development in the
BOB.1/OBF.1-deficient mice might be due to CD22 up-regulation. Mice were generated
lacking both genes. In BOB.1/OBF.1×CD22 double-deficient mice, numbers of transitional B
cells in the bone marrow were normal. Consequently, double-deficient mice also had normal
B to T cell ratios in the spleen. We show that BOB.1/OBF.1–/– B cells were incapable to
induce BCR-triggered Ca2+ mobilization. This Ca2+-signalling defect was restored in BOB.1/
OBF.1×CD22 double-deficient B cells. Nevertheless, double-deficient animals were unable
to mount humoral immune responses and to form germinal centers. Finally, we demonstrate
that CD22–/– splenic B cells proliferate independently of BOB.1/OBF.1 upon stimulation with
LPS. These studies suggest that the B cell differentiation defect observed in BOB.1/OBF.1–/–
mice is BCR-signal dependent. However, the impairment in germinal center formation is
caused by a different mechanism.
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1 Introduction
Octamer-dependent transcription is critical at various
stages of B cell development [1]. Octamer motifs are
found in virtually all immunoglobulin heavy chain and
light chain promoters and in addition in various enhancer
elements present in immunoglobulin genes. The activity
of promoter octamer motifs is conferred by either of two
DNA binding proteins, namely Oct1 or Oct2, and a B cell
restricted co-activator protein BOB.1/OBF.1 (also known
as OCA-B) [2–8]. Inactivation of BOB.1/OBF.1 in the
mouse germ line revealed several distinct functions of
this transcriptional co-activator in the process of the B-
lymphoid development, differentiation and immune
response. In BOB.1/OBF.1-deficient mice early B cell
development in the bone marrow occurs comparable to
wild-type mice. However, the number of transitional B
cell is significantly reduced in the bone marrow [1].
Accordingly, the number of transitional B cells arriving in
the spleen is diminished in BOB.1/OBF.1–/– mice com-
pared to wild-type controls [1, 9]. Furthermore, BOB.1/
OBF.1–/– mice are greatly impaired in the production of
secondary immunoglobulins [7, 10]. As could be shown,
this defect is not due to a failure of the isotype switching
process, but rather to reduced levels of transcription
from normally switched immunoglobulin heavy-chain
loci [10]. Additionally, no germinal centers can be found
in BOB.1/OBF.1-deficient mice [7, 9, 10]. This is consis-
tent with several observations indicating that the level of
BOB.1/OBF.1 protein is up-regulated in germinal center
B lymphocytes [11, 12]. Up-regulation of BOB.1/OBF.1 in
the germinal centers is not only due to transcriptional
induction [11, 12] but also by a post-translational mecha-
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nisms [13, 14]. Recent investigations demonstrate that
the transcriptional co-activator regulates the expression
of the chemokine receptor BLR1, which is a major regu-
lator of the microenvironmental homing of B cells in lym-
phoid organs [15]. So far it is still unclear, how BOB.1/
OBF.1 influences the early stages of B-lymphoid differen-
tiation. When we compared the cell surface phenotype of
wild-type and BOB.1/OBF.1-deficient bone marrow B
cells, we realized that CD22 is up-regulated in cells lack-
ing BOB.1/OBF.1, suggesting that a higher expression of
this inhibitory molecule may cause the observed devel-
opmental block.
The expression of CD22, a B lineage-restricted adhesion
receptor, begins at the pre-B cell stage [16, 17] and
steadily increases during development in the bone mar-
row. The role of CD22 during early B cell development is
largely unknown, while mature, long-lived B cells require
CD22 for recirculating back to the bone marrow [18]. Fur-
thermore, CD22 acts as an inhibitory accessory mole-
cule modulating the BCR-initiated signal. The negative
role of CD22 was proven by the generation of CD22
knockout mice [16, 19–21]. Upon BCR cross-linking in
the CD22-deficient B cells, an increased and prolonged
Ca2+ signal can be measured [16, 19–21]. In CD22–/–
mice, mature B cells circulate in a pre-activated stage
and show a pronounced susceptibility to apoptosis, as
well as an increased turnover rate [16]. Independently of
the BCR-initiated signal, CD22-deficient B cells respond
with increased proliferation upon LPS treatment. So far,
the mechanisms resulting in this augmented proliferation
are unclear. Since BOB.1/OBF.1 expression is induced in
B cells upon LPS stimulation, we checked the expres-
sion level of the co-activator in CD22–/– B cells upon LPS
treatment and could detect a much higher BOB.1/OBF.1
protein level compared to control B cells. The over-
expression of CD22 on BOB.1/OBF.1–/– pre-B cells and
the increased protein level of BOB.1/OBF.1 in CD22–/– B
cells upon LPS stimulation encouraged us to cross
BOB.1/OBF.1–/–×CD22–/– mice, to analyze whether their
signaling pathways are functionally connected.
2 Results
2.1 Increased surface expression of CD22 on B
cell precursors in BOB.1/OBF.1–/– mice
To further investigate the impairment in B cell differentia-
tion in BOB.1/OBF.1–/– mice, expression of various cell
surface molecules of wild-type and BOB.1/OBF.1–/– bone
marrow and spleen B cells were compared. We per-
formed three-color stainings of bone marrow cells iso-
lated from wild-type and BOB.1/OBF.1–/– mice. By these
stainings an increased expression level of the B-lineage
specific cell surface protein CD22 was observed
(Fig. 1A). Concordant with previous data [16, 17], stain-
ing of wild-type bone marrow cells with CD22 specific
antibody separated the B220/CD45+ B cell into three dif-
ferent CD22-expressing populations. High expression
level of CD22 characterized mature, recirculating B cells
(B220highIgMlow), whereas immature (B220lowIgMmed) and
transitional B (B220low/highIgMhigh) cells expressed an inter-
mediate and pre-B cells (B220lowIgMneg) a low level of
CD22. Bone marrow B cells isolated from BOB.1/OBF.1-
deficient mice showed increased expression of CD22
(Fig. 1A). Interestingly, this increase of CD22 expression
in BOB.1/OBF.1-deficient B cells was most pronounced
on the pre-B cells and immature B cells in the bone mar-
row, but also found on CD22high-expressing mature B
cells in the bone marrow and the spleen (Fig. 1A, B). In
contrast, the pre-B cell markers BP-1 and CD25 were
expressed at normal levels in BOB.1/OBF.1–/– mice
(Fig. 1C). Furthermore, the B220+HSAhigh population (pre-
B and immature B cells) expressed a similar HSA level in
both types of mice (Fig. 1C).
2.2 CD22 deficiency rescued development of
transitional B cells in BOB.1/OBF.1–/– mice
CD22 has been shown to act as a negative regulator of
the BCR-initiated signal in mature B cells [22]. Since
small changes of the CD22 expression level can already
show a phenotype [23], we considered the possibility
that the up-regulation of CD22 expression on B cell pre-
cursors may be responsible for the developmental block
observed in the bone marrow of BOB.1/OBF.1-deficient
mice. To further investigate this hypothesis, BOB.1/
OBF.1–/– mice were crossed with mice deficient in CD22
and the bone marrow of BOB.1/OBF.1×CD22 double-
deficient mice was analyzed. As has been previously
described [1], development of pro-, pre- and immature B
cells in BOB.1/OBF.1–/– mice occurred normal, while the
number of transitional and recirculating B cells was
reduced. CD22 deficiency did not interfere with B cell
development in the bone marrow, resulting in normal
numbers of transitional B cells [16]. However, recirculat-
ing B cells were almost absent due to a homing defect of
CD22-deficient B cells [18]. Using anti-B220 and anti-
IgM antibodies allowed us to distinguish pro- and pre-
(B220lowIgMneg), immature (B220lowIgMmed), transitional
(B220low/highIgMhigh) and recirculating (B220highIgMlow) B
cells. Bone marrow B cells isolated from BOB.1/
OBF.1×CD22 double-deficient mice revealed a signifi-
cantly augmented number of transitional B cells com-
pared to BOB.1/OBF.1–/– mice, almost achieving wild-
type level (Fig. 2). These data were consistent with the
hypothesis that the defect of early B cell development
observed in BOB.1/OBF.1–/– animals might be due to the
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Fig. 1. Altered CD22 expression pattern in the bone marrow of BOB.1/OBF.1–/– mice. (A) Bone marrow cells from wild-type and
BOB.1/OBF.1–/– mice were stained with anti-B220-FITC, anti-IgM-biotin and anti-CD22-PE antibodies. Lymphocytes were gated
for pro- and pre B cells (B220lowIgMneg, G1), immature B cells (B220lowIgMlow, G2), transitional (B220low/highIgMhigh, G3) and mature,
recirculating B cells (B220highIgMlow, G4). Histograms present the CD22 expression levels of BOB.1/OBF.1–/– and wild-type mice
of the indicated gates. Mean fluorescence intensities (MFI) for wild-type (black) and BOB.1/OBF.1-deficient (red) samples are
given. (B) Splenocytes from wild-type and BOB.1/OBF.1 –/– mice were gated for B220+ cells and a histogram showing CD22 stain-
ing with MFI is given. (C) Expression of CD25, BP1 and HSA on B220+ bone marrow cells from wild-type and BOB.1/OBF.1–/–
mice. Data are representative out of four experiments.
Fig. 2. Development of B cells in the bone marrow was res-
cued in BOB.1/OBF.1×CD22 double-deficient mice. Bone
marrow cells were isolated from wild-type, CD22–/–, BOB.1/
OBF.1–/–, and BOB.1/OBF.1×CD22–/– mice, stained with the
combination of anti-B220-FITC and anti-IgM-PE antibodies
and analyzed by flow cytometry. One representative out of 6
staining is shown. Mean percentages with SD of transitional
(B220low-medIgMhigh) and recirculating (B220highIgMlow) B cells
are given.
increased inhibitory influence on the BCR-signal, since
CD22 was higher expressed on precursor B cells. Never-
theless, the defect in recirculating B cells in the bone
marrow of BOB.1/OBF.1–/– mice could not be rescued in
double knockout mice.
2.3 Rescued B to T cell ratio in the spleen of
BOB.1/OBF.1×CD22 double–deficient mice
BOB.1/OBF.1-deficient mice revealed a two- to fourfold
reduced number of splenic B cells [1, 7, 9]. Since cross-
ing of BOB.1/OBF.1×CD22 deficiencies led to virtually
normal numbers of transitional B cells in the bone mar-
row, further investigations were done to clarify, whether
this rescue might result in the appearance of normal B
cell numbers in the periphery. Indeed, comparing T and
B cell populations showed that CD22 deficiency
increased the B to T cell ratio in the spleen of BOB.1/
OBF.1–/– mice (Fig. 3A). To analyze the different B cell
subpopulations in the spleen of BOB.1/OBF.1×CD22
double-deficient mice, anti-IgM versus anti-IgD stainings
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Fig. 3. B to T cell ratio in the spleen of BOB.1/OBF.1×CD22 double-deficient mice comparable to wild-type mice. (A) Splenic B
cells from mice with indicated genotype were stained with anti-B220-FITC and anti-CD3-PE. Mean percentages of T and B cells
are given. (B) Splenic cells are stained with anti-B220-biotin, anti-IgM-PE and anti-IgD-FITC antibodies. B220+ cells were gated
and mean percentages of total B cells, transitional T1 (IgMhighIgDlow), transitional T2 (IgMhighIgDhigh) [26] and mature (IgMlowIgDhigh)
B cell populations from one representative experiment are denoted. Mean percentages of mature (IgMlowIgDhigh) B cells obtained
in four independent experiments were 47.67±3.99 (wild-type), 48.81±5.46 (CD22–/–), 21.88±4.16 (BOB.1/OBF.1–/–) and
34.81±4.43 (BOB.1/OBF. 1×CD22–/–).
Fig. 4. CD22 deficiency rescued Ca2+ mobilization in BOB.1/
OBF.1–/– splenic B cells. Splenic B cells of wild-type, CD22–/–,
BOB.1/OBF.1–/–, and BOB.1/OBF.1×CD22 double-deficient
mice were stimulated with 10 ? g/ml B7–6 (anti-IgM anti-
body) at the time point indicated by the arrow within the fig-
ure. Ca2+ mobilization can be determined by the ratio of
bound to unbound Indo-1. One typical experiment out of five
with identical results is shown.
were done. BOB.1/OBF.1 deficiency resulted in the
reduction of IgMlowIgDhigh mature splenic B cells. In con-
trast, CD22 deficiency enhanced maturation of B cells in
the periphery, since in CD22–/– mice the relative number
of IgMlowIgDhigh cells was slightly increased [16]. In the
spleen of BOB.1/OBF.1×CD22 double-deficient mice the
population of IgMlowIgDhigh mature B cells increased, but
did not reach wild-type level (Fig. 3B).
2.4 Ca2+ mobilization was restored in BOB.1/
OBF.1×CD22 double-deficient splenic B cells
Having shown the developmental rescue of transitional B
cells in the bone marrow and an increase of mature B
cells in the spleen of BOB.1/OBF.1×CD22 double-
deficient mice, we looked for possible mechanisms.
Therefore, the signaling capacity of the BCR of BOB.1/
OBF.1–/– and BOB.1/OBF.1×CD22–/– B cells was com-
pared. Splenocytes of BOB.1/OBF.1–/–, CD22–/–, double-
deficient and control mice were stimulated by cross-
linking the BCR and the initiated Ca2+ mobilization was
measured (Fig. 4). As expected, the Ca2+ mobilization of
CD22–/– splenic B cells was augmented, whereas in
BOB.1/OBF.1–/– B cells Ca2+ mobilization stayed just
above background level. Thereby we demonstrated for
the first time, that defective BCR signaling in BOB.1/
OBF.1-deficient B cells was caused by a lack of Ca2+
mobilization. When analyzing BOB.1/OBF.1×CD22
double-deficient splenic B cells, the Ca2+ level was even
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Fig. 5. Analysis of T cell dependent immune response. Wild-
type, CD22–/–, BOB.1/OBF.1–/–, and BOB.1/OBF.1×CD22
double-deficient mice were immunized i.p. with 10 ? g/ml
TNP-OVA at day 0, and boosted at day 14. Blood of the
immunized mice was taken at days 0, 7, 14, and 21 and
immune response was determined by measuring TNP-
specific IgG1 levels by ELISA. Each symbol represents one
individual. The arrows indicate the day of TNP-OVA injec-
tion. For day 14 only the indicated mouse sera were avail-
able. One typical out of two experiments is shown.
Fig. 6. Analysis of germinal centers formation. Wild-type,
CD22–/–, BOB.1/OBF.1–/–, and BOB.1/OBF.1×CD22 double-
deficient mice were immunized i.p. with 10 ? g/ml TNP-OVA
at day 0, and boosted at day 14. At day 21 mice were killed
and spleens were subjected to histological stainings. Spleen
sections, 4 ? m thick, were stained with biotin-labeled PNA.
Binding of PNA to germinal centers is visualized using
streptavidin-HRP and AEC compound as a substrate. Sec-
tions were counterstained with hematoxylin and analyzed
using Leica microscope and OpenLab software.
higher than in control B cells, but not reaching the level
of CD22-deficient B cells. We could show that the almost
undetectable Ca2+ signal of BOB.1/OBF.1–/– B cells was
enhanced to at least wild-type level by deleting CD22.
2.5 Antigen-dependent immune responses in
BOB.1/OBF.1×CD22–/– mice
BOB.1/OBF.1 is not only involved in B cells develop-
ment, but also has an important role in antigen-
dependent B cell responses. In the absence of BOB.1/
OBF.1, thymus-dependent immune responses and ger-
minal center formation do not take place [7, 9, 10]. To
analyze, whether antibody responses were rescued in
BOB.1/OBF.1×CD22 double-deficient mice, we tested T
cell-dependent immune response. Therefore, mice of all
genotypes were immunized twice with TNP-ovalbumin
(TNP-OVA) and serum titers of anti-TNP specific IgM and
IgG1 antibodies were measured. While immunization of
wild-type and CD22–/– mice with TNP-OVA led to a
strong anti-TNP IgG1 production, BOB.1/OBF.1–/– mice
showed no primary IgG1 response and only a minor sec-
ondary response in this experiment. Similarly, double-
deficient mice generated no TNP-specific IgG1anti-
bodies (Fig. 5). However, both BOB.1/OBF.1–/– and dou-
ble knockout mice mounted a significant IgM primary
response to TNP-OVA (not shown). Also, total Ig levels of
all isotypes were similarly decreased in BOB.1/OBF.1
and double knockout mice (data not shown). Finally, the
spleens of TNP-OVA immunized mice were analyzed for
the presence of germinal centers. Staining with PNA
revealed germinal centers in the spleens of wild-type and
CD22–/– mice. As expected, germinal centers were not
detectable in the splenic follicles of immunized BOB.1/
OBF.1–/– mice (Fig. 6). Likewise, no germinal centers were
observed in PNA-stained spleen sections from immu-
nized double-deficient mice.
2.6 LPS stimulation induced an earlier onset and
increased expression of BOB.1/OBF.1 in
CD22–/– splenic B cells
CD22-deficient B cells showed an enhanced proliferative
response upon treatment with the mitogen LPS [16, 20].
Trying to elucidate the mechanism for this, we looked at
downstream LPS signaling pathways including the tran-
scriptional co-activator BOB.1/OBF.1. Purified splenic B
cells from wild-type and CD22–/– mice were stimulated
for 12, 24, 36 or 48 h with LPS. The proliferative
response as well as the expression level of BOB.1/OBF.1
were examined. In Fig. 7 the expression of BOB.1/OBF.1
at the protein level is shown. While unstimulated CD22–/–
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Fig. 7. Increased BOB.1/OBF.1 protein level in CD22–/– B
cells upon LPS stimulation. T cell depleted splenic B cells
out of CD22–/– and wild-type mice were stimulated with
15 ? g/ml LPS. Proliferation was stopped at the indicated
time points by lysing the cells. Comparable protein concen-
trations were analyzed by staining the Western blot with
anti-BOB.1/OBF.1 and anti-Cyclin A antibodies. Rel A stain-
ing was performed as loading control. Unstimulated B cells
are indicated as time point zero and untreated PD31 cells
were used as positive control.
Fig. 8. BOB.1/OBF.1×CD22 double-deficient splenic B cells
proliferate comparably to CD22–/– B cells upon stimulation
with LPS. Proliferative response of wild-type, CD22–/–,
BOB.1/OBF.1–/–, or BOB.1/OBF.1 × CD22 double-deficient
splenic B cells was measured as [3H]thymidine incorporation
upon 24-h stimulation with the indicated concentration of
LPS. The graph shows the mean of triplicates and the corre-
sponding standard deviations.or control B cells expressed BOB.1/OBF.1 at comparable
low levels, the amount of the co-activator could be
induced much faster and to a higher extent in CD22-
deficient B cells upon stimulation with LPS. An indication
for the enhanced proliferation of CD22–/– B cells was the
simultaneous probing of the blot with a Cyclin A anti-
body, since Cyclin A is required for activating the DNA
replication machinery during the interphase of the cell
cycle (Fig. 7).
2.7 Proliferation of LPS stimulated BOB.1/
OBF.1×CD22 double-deficient B cells
T cell depleted splenic B cells of BOB.1/OBF.1–/–,
CD22–/–, double-deficient, and control mice were stimu-
lated with the indicated concentrations of LPS for 24 h
(Fig. 8). BOB.1/OBF.1–/– B cells showed a similar
response as wild-type B cells to LPS treatment, whereas
CD22–/– B cells proliferated about twice as high as con-
trol cells, even at a concentration as low as 0.5 ? g/ml
LPS. Surprisingly, double-deficient B cells proliferated at
least as well as CD22–/– B cells (Fig. 8). We can conclude
from these results that the increased BOB.1/OBF.1
expression is not crucial for the increased proliferative
response of CD22–/– B cells upon stimulation with LPS.
3 Discussion
As has recently been described, B cells in BOB.1/
OBF.1–/– mice have a developmental block at the transi-
tional B cell stage [1]. In the present study, a potential
candidate causing the developmental block could be
identified, namely the adhesion molecule CD22. The
expression level of CD22 was increased on B-lineage
cells in the bone marrow of BOB.1/OBF.1–/– mice com-
pared to wild-type bone marrow cells. When analyzing
bone marrow B cells of BOB.1/OBF.1×CD22 double-
deficient mice, we found that development was rescued
resulting in normal numbers of transitional B cells. Fur-
thermore, this increased cell number contributed to an
almost wild-type ratio of B to T cells in the spleen of
double-deficient mice. More mature IgMlowIgDhigh B cells
were found in the spleen, but did not reach the number
found in control mice. Subsequently, the capacity of
BOB.1/OBF.1–/– and double-deficient splenic B cells to
initiate BCR signaling was determined by measuring
Ca2+ mobilization upon BCR cross-linking. BOB.1/
OBF.1–/– splenic B cells were unable to induce Ca2+ sig-
nals, whereas double-deficient B cells revealed an at
least wild-type Ca2+ flux. However, upon immunization
with antigen inducing a T cell-dependent immune
response, no Ag-specific IgG1 antibodies or germinal
center formation was detectable in double-deficient
mice. In CD22-deficient B cells, we observed an earlier
onset and an increased level of BOB.1/OBF.1 protein
upon stimulation with LPS. To narrow down the role of
BOB.1/OBF.1 in LPS-induced signaling, BOB.1/
OBF.1×CD22–/– B cells were subjected to proliferation
assays. The transcriptional co-activator appeared not to
be a crucial downstream target in the LPS pathway,
since in BOB.1/OBF.1–/– and in BOB.1/OBF.1×CD22
double-deficient B cells the LPS response occurred
independently of BOB.1/OBF.1.
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BOB.1/OBF.1 deficiency seems to modify the expression
level of CD22, as we could show by the increased sur-
face expression of CD22 on B lineage cells. CD22 can be
detected on the surface of wild-type bone marrow B
cells beginning at the pre-B cells stage and steadily
increasing during developmental progression [16, 17].
So far, the function of CD22 during B cell development is
not clear, because B cell maturation in CD22-deficient
mice occurs normal. Since CD22 is a negative regulator
of the BCR signaling, an increased CD22 expression
may suppress BCR-dependent differentiation in the
bone marrow. Thus, the block in development to the
transitional B cell stage in BOB.1/OBF.1–/– mice may be
mechanistically explained by the higher CD22 expres-
sion pattern of the immature B cell population. Addition-
ally, CD22 may already suppress differentiation at the
pre-B cell stage by inhibiting the pre-BCR signal. Pre-B
cells require a pre-BCR signal to expand and enter the
next differentiation stage [24]. However, it is not known
whether CD22 can modulate the pre-BCR signal.
The development of BOB.1/OBF.1–/– B cells in the bone
marrow can be rescued by the addition of the CD22 defi-
ciency, therefore, we expected to find expanded B cell
populations in the periphery. This was confirmed by an
almost wild-type B to T cell ratio and an increase of
IgMlowIgDhigh mature, long-lived B cells in the spleen of
BOB.1/OBF.1×CD22 double-deficient mice. We specu-
lated that this would result from a stronger BCR signal
which forces immature B cells to proceed in develop-
ment, as has been described for CD22-deficient B cells
[16, 19–21]. To analyze the signaling capacity of splenic
B cells, Ca2+ mobilization was measured upon BCR
engagement. In BOB.1/OBF.1–/– B cells almost no Ca2+
mobilization can be detected, whereas in BOB.1/
OBF.1×CD22 double-deficient B cells the Ca2+ level is
clearly increased. These results show for the first time
that the BCR-initiated Ca2+ signal is strongly affected in
BOB.1/OBF.1–/– B cells. Supposedly, the co-activator is
essential for regulating the expression of so-far-
unidentified signaling molecules, which are involved in
Ca2+ mobilization. Additionally, the increased CD22
expression level of BOB.1/OBF.1 –/– B cells probably also
contributes to the decrease of Ca2+ mobilization. When
BOB.1/OBF.1 and CD22 deficiencies were combined,
the inability to initiate a Ca2+ signal can be corrected. We
have demonstrated that the CD22 deficiency can com-
pensate the defective Ca2+ signaling of BOB.1/OBF.1–/– B
cells. Whether or not the BOB.1/OBF.1 and the CD22
signaling pathways are coupled, we cannot conclude
from our data. However, the Ca2+ mobilization initiated in
double-deficient mice might not only be important for
maturation in the periphery, but might also cause the
developmental rescue in the bone marrow. Supposedly,
BCR signal-dependent developmental checkpoints are
rescued by the higher Ca2+ signal in the bone marrow of
BOB.1/OBF.1×CD22 double-deficient B cells.
As just discussed for the rescue of B cell differentiation in
double-deficient mice, the pathways initiated by the
BCR might explain the defect of BOB.1/OBF.1–/– B cells.
Stimulation of BOB.1/OBF.1-deficient B cells with anti-
IgM antibodies leads to a fourfold reduction in prolifera-
tion, whereas the addition of T cell-derived signals like
IL-4 or CD40 improve the proliferative response [10]. T
cell-dependent immune responses do not exclusively
depend on the BCR signal, but also on cytokines such as
IL-4, co-stimulatory molecules like CD40 and B7, as well
as on chemokines. Therefore, we wondered, whether a T
cell-dependent immune response could be induced in
BOB.1/OBF.1×CD22–/– mice. However, neither the pro-
duction of TNP-specific IgG1 antibodies, nor germinal
center formation were improved. This was not all that
surprising, since in CD22–/– mice no increased T cell-
dependent response can be found, suggesting that
CD22 is not crucial for the T cell-dependent immune
response. In contrast, BOB.1/OBF.1–/– mice lack the for-
mation of germinal centers, which indicates the require-
ment of the transcriptional co-activator. One explanation
for the inability to form germinal centers could be that
BOB.1/OBF.1 is critical for the transcription of the che-
mokine receptor BLR1, which guides B cells into B cell
follicles [15, 25].
Finally, we also checked the responsiveness of BOB.1/
OBF.1–/– splenic B cells upon stimulation with LPS. These
cells proliferate at a comparable level to wild-type B
cells, demonstrating that the activation pathway initiated
by LPS is not affected by the BOB.1/OBF.1 deficiency.
When CD22–/– B cells are treated with LPS, they show a
higher proliferation rate and increased BOB.1/OBF.1
induction compared to wild-type B cells. We therefore
speculated, that the up-regulation of BOB.1/OBF.1 may
be mechanistically involved in the increased proliferation
of CD22-deficient B cells. However, stimulating BOB.1/
OBF.1×CD22 double-deficient splenic B cells with LPS
revealed that those B cells proliferate at least as strong
as CD22-deficient B cells. This finding indicates that
BOB.1/OBF.1 does not have an essential role in LPS-
induced proliferation. Thus, the mechanism by which
LPS-induced proliferation is increased in CD22-deficient
B cells is still not solved.
Overall we can conclude that by deleting CD22 in
BOB.1/OBF.1–/– mice the B cell development in the bone
marrow is rescued. Furthermore, the number of mature B
cells in the periphery increases, but does not reach wild-
type level. The reason for this improvement seems to be
the Ca2+ mobilization in double-deficient splenic B cells
that is comparable to that of wild-type B cells. In addition
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to the impairment of BOB.1/OBF.1–/– B cells to initiate
BCR signals, other mechanisms are also affected as can
be seen by the lack of T cell-dependent immune
responses, which can not be rescued by crossing in
CD22 deficiency. In addition, we showed that BOB.1/
OBF.1 is not essential in LPS-induced proliferation in
CD22-deficient B cells.
4 Materials and methods
4.1 Mice
C57BL/6 wild-type, BOB.1/OBF.1–/–, CD22–/– and BOB.1/
OBF.1×CD22 double-deficient mice on the same genetic
background were obtained from our breeding facility. Mice
were analyzed 8–12 weeks after birth. We tried to use litter-
mates for each experiment.
4.2 Flow cytometry analysis
Single-cell suspensions of Lympholyte-M (Cedarlane, Labo-
ratories Ltd., Ontario, Canada) purified splenocytes (5×105)
were incubated for 30 min at +4°C with different combina-
tions (as indicated in the results section) of the following
antibodies: anti-B220-FITC, anti-IgM-PE, anti-IgD-biotin,
anti-CD3-PE and anti-CD22-PE (all produced by PharMin-
gen, San Diego, CA). Suspensions of bone marrow cells
obtained by conventional method were stained with combi-
nations of anti-B220-FITC, anti-IgM-PE or anti-IgM-biotin,
anti-CD22-PE, anti-CD25-biotin, anti-HSA-biotin and anti-
BP1-biotin. Stainings were performed in PBS containing 0.1
% BSA (Roche Diagnostics, Mannheim, Germany), 0.1%
sodium azide and saturating concentration of anti-CD16/
CD32 (PharMingen) to block Fc + III/II receptors. Biotin-
labeled antibody was revealed by streptavidin-CyChrom
(PharMingen). Cell surface marker expression was analyzed
using a four-color flow cytometer (FACScalibur) and Cell-
Quest Software (Becton Dickinson, Heidelberg, Germany).
4.3 Measurement of Ca2+ movement
Splenic B cells from indicated mice were loaded with 4.5 ? M
Indo-1 plus 0.003% pluronic F-127 (both Molecular Probes,
Eugene, OR) in RPMI containing 1% fetal calf serum for
45 min at 37°C. Staining was performed on ice for 30 min
with biotinylated antibodies against CD11b (MAC.1) and
Thy1.2, followed by streptavidin-PE (all PharMingen). Ca2+
movement was measured upon stimulation with 10 ? g/ml
B7–6 monoclonal anti-IgM antibody on gated MAC.1- and
Thy1.2-negative B cells.
4.4 Immunization
BOB.1/OBF.1–/–, CD22–/–, double-deficient and control mice
of 10–12 weeks age were immunized i.p. with 100 ? g TNP13-
OVA (Biosearch Technologies, Novato, CA) preincubated in
Alu-Gel-S (Serva, Boehringer Ingelheim, Heidelberg, Ger-
many) at day 0 and boosted at day 14. Mice were bleed at
days 0, 7, 14 and 21. TNP-specific antibody levels were
determined by ELISA with TNP17-BSA (Biosearch Technolo-
gies) coated polysorb plates (Nalge Nunc, Rochester, NY).
Sera were applied in serial dilutions onto the plates. Con-
centration of IgM and IgG1 levels were determined using
goat anti-IgM or anti-IgG1 alkaline phosphatase-linked anti-
bodies and the substrate p-nitrophenyl phosphate. As an
internal standard for each plate, independent sera were
pooled and diluted as described. This served as an arbitrary
standard defining arbitrary units.
4.5 Proliferation assay
Splenocytes from the indicated animals were T cell depleted
by pretreating the cells with anti-CD4 and anti-CD8 IgM anti-
bodies on ice and incubating them with baby rabbit comple-
ment (Cedarlane, Ontario) for 45 min at 37°C afterwards. For
stimulation 1×105 B cells in RPMI containing 5% fetal calf
serum were supplemented with different concentration of
LPS (Calbiochem, Novabiochem, Darmstadt) for 24 h. Prolif-
eration was measured by [3H]thymidine incorporation (1 ? Ci/
well) during the last 10 h of culture.
4.6 Immunohistochemistry
Spleens were embedded in Tissue-Tek O.C.T. compound
(Sakura, The Netherlands), snap frozen in liquid nitrogen and
stored at –80°C. Cryostat sections of 4 ? m were prepared,
air dried, and fixed in acetone (10 min at room temperature).
Slides were stained 30 min with 20 ? g/ml of PNA-biotin
(Vector, CA) in 150 mM NaCl, 10 mM Hepes, pH 7.5. After
washing, slides were incubated with 1:100 dilution of
streptavidin-biotinylated horseradish peroxidase (HRP;
Amersham, GB). Staining is visualized using AEC compound
(Sigma), followed by counterstaining with hematoxylin
(Sigma). Slides were mounted with Kaiser’s glycerol gelatin
(Merck, Germany) and analyzed using a Leica microscope
(DMIRB/E) and OpenLab software (version 2.2.5).
4.7 Western blot
T cell-depleted splenocytes from wild-type and CD22–/–
mice were stimulated with 15 ? g/ml LPS (Calbiochem,
Novabiochem, Darmstadt) for 12, 24, 36 and 48 h. Buffer
used for cell lysis consisted of 20 mM Tris pH 7.5, 1 mM
EDTA, 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate and 0.1% SDS. Proteins were resolved on a 12.5%
SDS-polyacrylamide gel and transferred on PVDF mem-
brane (Millipore). For immunoblotting of BOB.1/OBF.1 poly-
clonal rabbit anti-BOB.1/OBF.1 antibody was used. For
detection of Rel A and Cyclin A antibodies from Santa Cruz
were purchased. Proteins were visualized using donkey anti-
2488 T. Samardzic et al. Eur. J. Immunol. 2002. 32: 2481–2489
rabbit HRP-conjugated antibody (Santa Cruz) and ECL
detection system (Amersham).
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